Ototoxicity

Adverse Drug Reactions and Toxicological Reviews

Volumn 17, Issue 2-3, 1998, Pages 75-89

  Tange, R A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Aminoglycosides; Cisplatinum; Erythromycin; Loop diuretics; Minocycline; Ototoxicity; Quinine; Salicylates; Streptomycin; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; CISPLATIN; ERYTHROMYCIN; LOOP DIURETIC AGENT; MINOCYCLINE; QUININE; SALICYLIC ACID DERIVATIVE; STREPTOMYCIN; VANCOMYCIN;

AUDIOMETRY; CLINICAL FEATURE; COCHLEA; HISTOPATHOLOGY; HUMAN; OTOTOXICITY; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CISPLATIN; DIURETICS; EAR DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS; QUININE; SALICYLATES; TINNITUS;

EID: 0031793777     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Morton R. seu Exercittationes de Morbus Univeralibus acutis 1692; p 132.
2. Muller J. Nebenwirkung von medikamente. Berl Klin Wochenschr 1877; 14: 29-31.
3. Jager B, Alway R. The treatment of acute rheumatic fever with large doses of sodium salicylate. Am J Med Sci 1946; 211: 273-5.
4. Waksman SA, Bugie E, Schatz A. Isolation of antibiotic substances from soil microorganisms with special reference to streptothricin and streptomycin. Mayo Clin Proc 1944; 19: 537-48.
5. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 1944; 55: 66-7.
6. Black FO, Peszneckter SC Vestibular ototoxicity: clinical considerations. In: Rybak LP, ed. Ototoxicity. Otolaryngol Clin North Am. Philadephia: WB Saunders, 1993: 713-34.
7. Tange RA, Dreschler WA, van der Hulst RJM. The importance of high-tone audiometry in ototoxicity monitoring. Arch Otorhinolaryngol 1985; 242: 77-81.
8. van der Hulst RJ, Boeschoten EW, Nielsen FW, Struijk DG, Dreschler WA, Tange RA. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL J Otorhinolaryngol Relat Spec 1991; 53: 19-22.
9. Maw AR. Bobbing oscillopsia. Ann Otol Rinol Laryngol 1971; 80: 233-9.
10. Rybak LP, Matz GJ. Ototoxicity. In: Alberti PW, Ruben RJ, eds. Otologic Medicine and Surgery. New York: Churchill Livingstone 1988: 1605.
11. Hinshaw HC, Feldman WH. Streptomycin in the treatment of clinical tuberculosis: a preliminary report. Mayo Clin Proc 1945; 20: 313.
12. Schuknecht HF. Pathology of the ear. 1976 Harvard University Press Cambridge. Massachusetts London.
13. Tange RA, Huizing EH. Hearing loss and inner ear changes in a patient suffering from severe gentamicin ototoxicity. Arch Otorhinolaryngol 1980; 228: 113-21.
14. Tange RA. Differences in the cochlear degeneration pattern in the guinea pig as a result of gentamicin and cis-platinum intoxication. Clin Otolaryngol 1984; 9: 323-7.
15. Tange RA, Hodde KC. Microvasculature of the stria vascularis in the round window area in the rat: a scanning electron microscopy study. ORL J Otorhinolaryngol Relat Spec 1985; 47: 225-8.
16. Puel JL, Saffiedine S, Gervais d'Aldin C, Pujol R. Synaptic regeneration and functional recovery after excitotoxic injury in the guinea pig cochlea. Comptes Rendus de l'Academie des Sciences 1995; 318(1): 67-75.
17. Bignall JR, Crofton JW, Thomas JA. Effect of streptomycin on the vestibular function. BMJ 1951; 1: 554-9.
18. Farrington R, Hull-Smith H, Bunn P, McDermott W. Streptomycin toxicity. Reactions to highly purified drug on long-continued administration to human subjects. JAMA 1947; 134: 679-87.
19. Glorig A. The effect of dihydrostreptomycin hydrochloride and sulfate on auditory mechanism. Ann Otol Rhinol Laryngol 1951; 60: 327-35.
20. Waisbren B, Sprink W. A clinical appraisal of neomycin. Ann Intern Med 1951; 33: 1099.
21. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984; 13(Supplement A): 9-22.
22. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ. Highfrequency audio metric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992; 165: 1026-1032.
23. Prins JM, Büller HR, Kuijper E, Tange RA, Speelman P. Once versus trice daily gentamicin in patients with serious infections. Lancet 1993; 341(Feb 6): 335-9.
24. Brushwood DB. Government liable for failure to monitor a patient's serum gentamicin concentration in an army hospital. Am J Hosp Pharm 1992; 49: 1748-50.
25. Usami S, Abe S, Kasai M, Shikawa H, Moeller B, Kenyon JB, Kimberling WJ. Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. Laryngoscope 1997; 107: 483-90.
26. Rosenberg B, van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9.
27. Rosenberg B, van Camp L, Trosko J, Mansour V. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-6.
28. Daley-Yates PT, McBrien DCH. The mechanism of renal clearance of cisplatin and its modification by furosemide and probenecid. Biochem Pharmacol 1982; 31: 2243-6.
29. Harder HC, Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein synthesis in mammalian cells in vitro. Int J Cancer 1970; 6: 207-16.
30. Talley RW, O'Bryan RM, Gutterman JU. Clinical evaluation of ototoxic effects of cis-diamminochloroplatinum (NSC-119875)-phase I clinical study. Cancer Chemother Rep 1973; 57: 465-71.
31. Peil IJ, Perlia CP. Phase II study of cis-diamminochloroplatinum II (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies. Cancer Chemother Rep 1975; 59: 995-9.
32. Cvitkovic E, Spaulding J, Bethumne V, Matrin J. Improvement of cis-diamminochloroplatinum therapeutic index in an animal model. Cancer 1977; 39: 1372-81.
33. Rossof AH, Slayton RE, Perlia CP. Preliminary clinical experience with cis-diamminochloroplatinum II (NSC-119875). Cancer 1972; 30: 1451-6.
34. Hadley D, Herr HW. Peripheral neuropathy associated with cis-diamminochloroplatinum II (NSC-119875) treatment. Cancer 1979; 44: 2026-8.
35. Roelofs RI, Hrushesky W, Rogin J, Rosenberg B. Peripheral sensory neuropathy and cisplatinum chemotherapy. Neurology 1989; 34: 934-8.
36. Koppelman J, Budwick AS, Kramer MB. Ototoxicity of high-dose cisplatinum by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988; 98: 858-64.
37. Stengs CH, Klis SF, Huizing EH, Smoorenburg GF. Cisplatinum-induced ototoxicity. Electrophysiological evidence of spontaneous recovery in albino guinea pigs. Hear Res 1997; 111: 103-13.
38. Stengs CH. Protection and recovery from cisplatinum-induced hearing loss. Thesis Utrecht 1998.
39. de Oliviera JAA. Audiovestibular toxicity of drugs. CRC Press, Inc., Boca Raton, Florida, 1989.
40. Zeyl van LG, Conijn EA, Rodenberg M, Tange RA. Analysis of hearing loss due to Cis-diamminodichloroplatinum-II. Arch Otorhinolaryngol 1984; 239: 255-62.
41. Vermorken JB, Kapteyn TS, Hart AAM, Pinedo HM. Ototoxicity of Cis-diamminodichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53-8.
42. Laurell G. Ototoxicity of the anticancer drug Cisplatin - clinical and experimental aspects. Scand Audiol 1991: supplement 33.
43. Maher JF, Schreiner GE. Studies on ethacrynic acid in patients with refractory oedema. Ann Intern Med 1965; 62: 15-29.
44. Wigand ME, Heidland A. Ototoxic side-effects of high doses of frusemide in patients with uraemia. Postgrad Med J 1971; (April suppl.): 54-6.
45. Forge A. The endolymphatic surface of the stria vascularis in the guinea pig and the effects of ethacrynic acid as shown by scanning electron microscopy. Clin Otolaryngol 1980; 5: 87-95.
46. Rifkin SI, DeQuesada AM, Pickering MJ. Deafness associated with oral furosemide. South Med J 1978; 71: 86-8.
47. Bourke E. Furosemide. bumetanide and ototoxicity. Lancet 1976; 1: 917-18.
48. Davis RE, Brummett RE, Benrick T, Himes. The ototoxic interactions of viomycin, capreomycin and polymyxin B with ethacrynic acid. Acta Otolaryngol 1982; 93: 211-17.
49. Laurell G, Engström B. The combined effect of Cisplatin and furosemide on the hearing function in guinea pig. Hear Res 1989; 38: 19-26.
50. Scherbel AL, Harrison JW, Atdjian M. Further observations on the use of 4-aminoquinolone compounds in patients with rheumatoid arthritis and related diseases. Cleve Clin J Med 1958; 25: 95-111.
51. Hart CW, Naunton RF. The ototoxicity of chloroquinine phosphate. Arch Otolaryngol 1964; 80: 407-12.
52. Ruedi L, Furrer W, Luthy F, Nager G, Tscherren B. Further observations concerning the toxic effects of streptomycin and quinine on the auditory organ on the guinea pig. Laryngoscope 1952; 62: 333-41.
53. Karlson KK, Flock B, Flock A. Ultrastructural changes in the outer hair cells of the guinea pig cochlea after exposure to quinine. Acta Otolaryngol 1991; 111(3): 500-5.
54. Rybak LP, Whitworth C. Quinine reduces noxious cochlear effects of furosemide and ethacrynic acid. Am J Otolaryngol 1988; 9(5): 238-43.
55. Alván G, Karlsson KK, Villén T. Reversible hearing impairment related to quinine blood concentrations in guinea pigs. Life Sci 1989; 45: 751-5.
56. Jung TT, Rhee CK, Lee CS, Park YS, Choi DC. Ototoxicity of salicylate, nonsteroidal antiinflammatory drugs, and quinine (review). Otolaryng Clin North Am 1993; 26(5): 791-810.
57. Nielsen-Abbring FW, Perenboom RM, Van der Hulst RJAM. Quinine-induced hearing loss. ORL J Otorhinolaryngol Relat Spec 1990; 52: 65-8.
58. Tange RA, Dreschler WA, Claessen FAP, Perenboom RM. Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparam infection. Auris Nasus Larynx 1997; 24: 131-6.
59. Muller G. Betrag zur wirkung der salicylsauren natrons beim diabetis melletus. Berl Klin Wochenschr 1877; 14: 29-31.
60. Gignoux M, Martin H, Cagfinger H. Troubles cochleo-vestibulaire après tentative de suicide à l'aspirine. J Fr Otolaryngol 1966; 15: 631-5.
61. Miller RR. Deafness due to plain and long-acting aspirin tablets. J Clin Pharmacol 1978; 18: 468-71.
62. Grigor RR, Spitz PW, Furst DE. Salicylate toxicity in elderly patients with rheumatoid arthritis. J Rheumatol 1987; 14: 60-6.
63. Geraci JE, Heilman FR, Nichols DR, William E. Vancomycin for acute endocarditis. Mayo Clin Proc 1958; 33: 172-81.
64. v d Hulst RJ, Boeschoten EW, Nielsen FW, Struijk DG, Dreschler WA, Tange RA. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL J Otorhinolaryngol Relat Spec 1991; 53: 19-22.
65. Tange RA, Kieviet HL, van Marie J, Bagger-Sjoback D, Ring W. An experimental study of vancomycin-induced cochlear damage. Arch Otorhinolaryngol 1989; 246: 67-70.
66. Brummett RE. Ototoxic liability of erythromycin and analogues. In: Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America Philadephia, WB Saunders, 1993: 810-11.
67. Eckman M, Johnson T, Reis R. Partial deafness after erythromycin. New Engl J Med 1975; 292: 649.
68. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91: 40-5.
69. Dabernat H, Delmas C, et al. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae determined by in-vitro and serum bactericidal test. J Antimicrob Chemother 1991; 27: 19-30.
70. McCready P. Inner ear deafness from tetanus antitoxin injection. Ann Otol Rhinol Laryngol 1938; 47: 247.
71. Stup HF, Kupper K, Lager F, Sous H, Quand M. Inner ear concentrations and ototoxicity of different antibiotics in local and systemical application. Audiology 1973; 12: 350-63.
72. Tommerup B, Moller K. A case of profound hearing loss secondary to the prolonged use of framycetin ear drops. J Laryngol Otol 1984; 98: 1135-7.
73. Podoshin L, Fradis M, Dacvis B. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol 1998; 103: 46-50.
74. Brummett RE, Harris RF, Lindgren JA. Detection of ototoxicity from drugs applied topically to the middle ear space. Laryngoscope 1976; 86: 1177.
75. Kellerhals B. Horschaden durch ototoxische ohrtropfen. Ergebnisse einer umfrage. HNO 1978; 26-2: 49-52.
76. Lundy LB, Graham MD. Ototoxicity and ototopical medications: a survey of otolaryngologists. Presented at the Ninth Sambaugh-Shea Weekend of Otology, Chicago, Illinois, March 6-8, 1992.
77. Morizono T, Sikora M. The ototoxicity of topically applied providone-iodine solutions. Arch Otolaryngol 1982; 108: 210-13.
78. Aursnes J. Vestibular damage from chlorhexidine in guinea pigs. Acta Oto-Laryngol 1981; 92: 89-100.
79. Tange RA. Adverse effects of drugs on the function of the inner ear. Adv Drug Reaction Bull 1997; 186: 707-10.